Aegerion Pharmaceuticals, Inc.

  • Did a Strong New Drug Make This Biotech Overvalued?

    By Brandy Betz - August 16, 2013 | Tickers: AEGR, ARIA, SNTS

    Santarus (NASDAQ: SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in the first quarter. The company already had four products on the market and has a trio of pipeline projects in development. Is now a good time to buy Santarus -- or has it become overvalued?

    Strong second quarter

    Second quarter revenues at Santarus grew 89% year-over-year to more »

  • Did Q2 Prove This Biotech Is Overvalued?

    By Brandy Betz - August 13, 2013 | Tickers: AEGR, ARIA, NVS, SNTS

    Ariad Pharmaceuticals (NASDAQ: ARIA) reported its second quarter results last week and focused the associated conference call on the company’s two drugs. Leukemia drug Iclusig is growing in sales but faces a market saturated with generics and a long-standing blockbuster from Novartis (NYSE: NVS).  And the oncologic pipeline project lost out on a Food and Drug Administration acceleration, which will put it further behind the competition.  

    Are Ariad’s more »

  • Orphan Drug Makers: Robust Investment Opportunities

    By Muhammad Abdullah - August 1, 2013 | Tickers: AEGR, BMRN, ISIS

    The US pharmaceutical industry has been revolutionized by the emerging biotech companies which have discovered new ways to cure even the rarest of diseases. So the concept of an orphan drug is no more a mystery for the people who invest into pharmaceutical companies. According to the findings of Thomson Reuters, at the end of 2011 orphan drug sales attributed to 6% of the total pharmaceutical sales. Along with that more »

  • Two Drugs Competing for an One-In-A-Million Disease

    By Kanak Kanti - July 31, 2013 | Tickers: AEGR, GILD, ISIS

    Both Isis Pharmaceuticals (NASDAQ: ISIS) and Aegerion Pharmaceuticals (NASDAQ: AEGR) have a single drug in the market that help heart patients deal with what is called bad cholesterol, or LDL. The particular disease they both target is called HoFH, and it is a very rare genetic disease. Both companies have similar levels of market capitalization, and the FDA approved their respective drug candidates within months of one another. There was more »

  • Will This Speculative Cholesterol Treatment Pay Off?

    By Leo Sun - July 30, 2013 | Tickers: AEGR, MRK, PFE

    In America, 33.5% of adults over the age of 20 have high LDL (“bad”) cholesterol levels, according to the CDC. Even though the American Heart Association states that people with high LDL levels exceeding 200 mg/dL are twice as likely to develop coronary heart disease, only half of adults in the U.S. seek treatment, often leading to premature death.

    This epidemic of high cholesterol levels across the more »

  • Is The Orphan Drug Buying Frenzy Over?

    By Ben Williams - July 17, 2013 | Tickers: ACAD, AEGR, ALXN, ONXX, VRTX

    Orphan drug stocks may have been the hottest and best performing sector of the market for the past year, but they have really been on fire for the past month and have frequently been the object of takeover rumors. The big question is, “Can this buying frenzy be sustained; or is the rally over, at least for the time being, now that orphan drug stocks appear to be leveling off more »

  • This Anti-Sense Bet Makes Sense

    By Mohsin Saeed - July 1, 2013 | Tickers: AEGR, AZN, ISIS

    In the last couple of years, the biotechnology industry has been on a roll. The large number of drug approvals and the dreaded patent cliff has positively impacted the biotechnology index. This has increased demand for small biotechnology companies with promising candidates and improved across the entire industry.

    Recently, Isis Pharmaceuticals (NASDAQ: ISIS) antisense platform has received a lot of attention. The company uses its antisense technology to eradicate proteins more »

  • A $90 Price Target for This Biotech! How’s It Figured?

    By Brian Nichols - May 31, 2013 | Tickers: AEGR, ALXN, REGN, SRPT

    Aegerion Pharmaceuticals (NASDAQ: AEGR) is currently trading higher by 13% after having its price target raised to $90 by Canaccord – which is now the highest target on the stock. The stock is trading at $68.50 after a one-year 380% gain due to the recent FDA approval of its drug Juxtapid. However, I believe the stock has gotten ahead of itself, and that there is no basis for a $90 more »

  • Dow's Over 15,000...What Do You Do?

    By Michael Mandala - May 30, 2013 | Tickers: AEGR, BF-A, EXXI, MSFT

    If there’s any time to be wary of the U.S. equity markets, now presents no better time. It was just a few short years ago the Dow Jones Industrial Average crossed over the 14,000 mark and most investors continued to dump money into long positions. Day after day, CNBC’s scrolling headlines highlighted the day’s advances with special notices saying, “Dow is so many points from more »

  • Too Many Questions Make This Thursday Mover a Sell

    By Brian Nichols - May 19, 2013 | Tickers: ACAD, AEGR, SNY

    Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR) rallied an incredible 31.37% on Thursday after a series of bullish notes that painted a clearer picture for its newly approved (rare-cholesterol disease) drug Juxtapid. While the company’s current market capitalization of $1.75 billion suggests that Aegerion has a potential blockbuster on its hand, the reality is not quite so bullish.

    What created the movement?

    Aegerion Pharmaceuticals had previously reported that more »

  • 3 Companies Insiders Love

    By Mohsin Saeed - March 28, 2013 | Tickers: AEGR, DOLE, JNS

    An interesting method of assessing the direction a stock can take is by monitoring insider purchases. This is because company insiders hold information about catalysts and industry trends, which is not available to other investors. Institutional investors also have vast resources at their disposal to assess the potential of stocks.

    This makes following insider and institutional buying trends an effective investment strategy. The following few companies have seen significant insider more »

  • Insider Siren: Should We Follow the “Whales” Into These Stocks?

    By Brian Gorban - January 30, 2013 | Tickers: AEGR, TST

    Every person involved in the stock market will tell you time and time again that being able to outperform the general market is no easy feat. In fact, 80% of fund managers year in and year out underperform the S&P 500 and has people wondering what is a strategy worth using? One strategy that has proven to be effective over time in determining whether a stock is moving higher more »

  • Hedge Funds Are Snapping Up These Stocks

    By Meena Krishnamsetty - January 18, 2013 | Tickers: AEGR, CPWR, LOGM, MRTN, RIG

    The most up-to-date publicly available information on hedge funds comes from 13D and 13G filings, which take place shortly after a fund or other institutional investor owns over 5% of a stock’s outstanding shares (or makes changes to that position at a later date), in addition to any other public disclosures made by the funds themselves or the company involved. We don’t recommend that every single investment by more »

  • Better Cancer Treatment: Partnerships and Dividends

    By Josef Ray Dagatan - January 17, 2013 | Tickers: AEGR, AZN, ISIS

    The quality of life that we live is determined in part by how healthy our physical being is. All of us get sick at one time or another, for which we consult a doctor who prescribes a medicine that helps us to regain our health. But as we all know, sicknesses such as cancer and other autoimmune diseases cannot be cured by over-the-counter drugs. Drugs for these kinds of ailments more »